Definitive Contract 75A50120C00169

This is a definitive cost-sharing contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, for the clinical development of a CRISPR-Cas3 phage cocktail to treat recurrent urinary tract infections caused by Escherichia coli, including antimicrobial and multi-drug resistant strains. The contract has a ceiling value of $91,817,550.73 and a completion date of December 31, 2026.

This award is related to a Broad Agency Announcement (BAA) issued by BARDA seeking proposals for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. Locus Biosciences is also working on a sub-contract from Trustees of Boston University to optimize a CRISPR-Cas3 phage cocktail targeting Klebsiella pneumoniae for a Phase 1 clinical trial, with the aim of addressing serious infections regardless of underlying drug resistance. The contract does not have a set-aside designation.